Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson's disease models

被引:13
|
作者
Liu, Lan-Xiang [1 ]
Du, Dan [1 ]
Wang, Zhan-Qiu [1 ]
Fang, Yuan [1 ]
Zheng, Tao [1 ]
Dong, Yan-Chao [2 ]
Shi, Qing-Lei [3 ]
Zhao, Min [4 ]
Xiao, Fang [4 ]
Du, Juan [5 ]
机构
[1] Qinhuangdao Municipal 1 Hosp, Dept Magnet Resonance Imaging, Qinhuangdao, Hebei, Peoples R China
[2] Qinhuangdao Municipal 1 Hosp, Dept Intervent, Qinhuangdao, Hebei, Peoples R China
[3] Siemens Ltd, Beijing, Peoples R China
[4] Qinhuangdao Municipal 1 Hosp, Dept Pathol, Qinhuangdao, Hebei, Peoples R China
[5] Hebei Med Univ, Shijiazhuang, Hebei, Peoples R China
关键词
nerve regeneration; fractional anisotropy; T2*; rotenone; 6-hydroxydopamine; Parkinson's disease; magnetic resonance imaging; diffusion tensor imaging; dopaminergic neurons; neural regeneration; WHITE-MATTER CHANGES; SUBSTANTIA-NIGRA; COMPLEX-I; DEGENERATION; MECHANISMS; DEPOSITION; TOXICITY; SYSTEM;
D O I
10.4103/1673-5374.235076
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Rotenone and 6-hydroxydopamine are two drugs commonly used to generate Parkinson's disease animal models. They not only achieve degenerative changes of dopaminergic neurons in the substantia nigra, but also satisfy the requirements for iron deposition. However, few studies have compared the characteristics of these two models by magnetic resonance imaging. In this study, rat models of Parkinson's disease were generated by injection of 3 mu g rotenone or 10 mu g 6-hydroxydopamine into the right substantia nigra. At 1, 2, 4, and 6 weeks after injection, coronal whole-brain T2-weighted imaging, transverse whole-brain T2-weighted imaging, and coronal diffusion tensor weighted imaging were conducted to measure fractional anisotropy and T2* values at the injury site. The fractional anisotropy value on the right side of the substantia nigra was remarkably lower at 6 weeks than at other time points in the rotenone group. In the 6-hydroxydopamine group, the fractional anisotropy value was decreased, but T2* values were increased on the right side of the substantia nigra at 1 week. Our findings confirm that the 6-hydroxydopamine-induced model is suitable for studying dopaminergic neurons over short periods, while the rotenone-induced model may be appropriate for studying the pathological and physiological processes of Parkinson's disease over long periods.
引用
收藏
页码:1276 / 1280
页数:5
相关论文
共 50 条
  • [31] Therapeutic potential of bromelain in 6-hydroxydopamine rat model of parkinson's disease
    Cicek, B.
    Gul, M.
    Taghizadehghalehjoughi, A.
    Okkay, U.
    Yildirim, S.
    Okkay, I. F.
    Ertugrul, M. S.
    Aydin, I. C.
    Bayram, C.
    Arslan, Y. K.
    Hacimuftuoglu, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S438 - S439
  • [32] The effect of thrombin on a 6-hydroxydopamine model of Parkinson's disease depends on timing
    Cannon, Jason R.
    Hua, Ya
    Richardson, Rudy J.
    Xi, Guohua
    Keep, Richard F.
    Schallert, Timothy
    BEHAVIOURAL BRAIN RESEARCH, 2007, 183 (02) : 161 - 168
  • [33] Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
    Galindo, Maria F.
    Solesio, Maria E.
    Atienzar-Aroca, Sandra
    Zamora, Maria J.
    Jordan Bueso, Joaquin
    PARKINSONS DISEASE, 2012, 2012
  • [34] Metabolic–dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson’s disease
    Cindy Casteels
    Erwin Lauwers
    Guy Bormans
    Veerle Baekelandt
    Koen Van Laere
    European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35 : 124 - 134
  • [35] Afobazole Restores the Dopamine Level in a 6-Hydroxydopamine Model of Parkinson’s Disease
    M. V. Voronin
    I. A. Kadnikov
    S. B. Seredenin
    Neurochemical Journal, 2019, 13 : 49 - 56
  • [36] Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease
    Morris, J. K.
    Zhang, H.
    Gupte, A. A.
    Bomhoff, G. L.
    Stanford, J. A.
    Geiger, P. C.
    BRAIN RESEARCH, 2008, 1240 : 185 - 195
  • [37] Parkinson's Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model
    da Fonseca, Victor Silva
    Goncalves, Valeria de Cassia
    Izidoro, Mario Augusto
    de Almeida, Antonio-Carlos Guimaraes
    Fonseca, Fernando Luiz Affonso
    Scorza, Fulvio Alexandre
    Finsterer, Josef
    Scorza, Carla Alessandra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (15)
  • [38] Afobazole Restores the Dopamine Level in a 6-Hydroxydopamine Model of Parkinson's Disease
    Voronin, M. V.
    Kadnikov, I. A.
    Seredenin, S. B.
    NEUROCHEMICAL JOURNAL, 2019, 13 (01) : 49 - 56
  • [39] The beneficial effect of vanillin on 6-hydroxydopamine rat model of Parkinson's disease
    Abuthawabeh, Rasha
    Abuirmeileh, Amjad N.
    Alzoubi, Karem H.
    RESTORATIVE NEUROLOGY AND NEUROSCIENCE, 2020, 38 (05) : 369 - 373
  • [40] Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson's disease
    Westphal, Robert
    Simmons, Camilla
    Mesquita, Michel B.
    Wood, Tobias C.
    Williams, Steve C. R.
    Vernon, Anthony C.
    Cash, Diana
    PLOS ONE, 2017, 12 (03):